Cargando…
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and rankin...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088334/ https://www.ncbi.nlm.nih.gov/pubmed/36779819 http://dx.doi.org/10.1177/10398562231156684 |
_version_ | 1785022556984573952 |
---|---|
author | Berger, Joshua J Fitzgerald, Paul B |
author_facet | Berger, Joshua J Fitzgerald, Paul B |
author_sort | Berger, Joshua J |
collection | PubMed |
description | OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions. RESULTS: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future. CONCLUSION: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists. |
format | Online Article Text |
id | pubmed-10088334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-100883342023-04-12 The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists Berger, Joshua J Fitzgerald, Paul B Australas Psychiatry Psychotropic Medication OBJECTIVE: To explore the knowledge and attitudes of psychiatrists about psychedelics therapies. METHOD: Access to a cross-sectional survey was distributed to psychiatrists through social media channels. Attitudes and knowledge about psychedelic therapies were recorded using Likert scales and ranking questions. RESULTS: Fifty-eight complete responses were collected (44 fully trained +14 trainee RANZCP members). Greater than 85% of respondents agreed there is a shortfall in effective psychiatric treatments, and greater than 65% agreed that psychedelic therapies might address this shortfall. The psychiatrists did not consider themselves knowledgeable about psychedelic therapies, with 60% showing interest in further training on this topic. About 70% of the sample hold various concerns about psychedelic therapies, and more believe that the prescription of psychedelics should be limited to psychiatrists in the future. CONCLUSION: Considering these results in the context of a rapidly changing landscape relating to psychedelic research and regulations, we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists. SAGE Publications 2023-02-13 2023-04 /pmc/articles/PMC10088334/ /pubmed/36779819 http://dx.doi.org/10.1177/10398562231156684 Text en © The Royal Australian and New Zealand College of Psychiatrists 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Psychotropic Medication Berger, Joshua J Fitzgerald, Paul B The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title | The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title_full | The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title_fullStr | The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title_full_unstemmed | The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title_short | The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists |
title_sort | prescription of psychedelic therapies in australia and new zealand: a brief survey of psychiatrists |
topic | Psychotropic Medication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088334/ https://www.ncbi.nlm.nih.gov/pubmed/36779819 http://dx.doi.org/10.1177/10398562231156684 |
work_keys_str_mv | AT bergerjoshuaj theprescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists AT fitzgeraldpaulb theprescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists AT bergerjoshuaj prescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists AT fitzgeraldpaulb prescriptionofpsychedelictherapiesinaustraliaandnewzealandabriefsurveyofpsychiatrists |